Daunoxome® Treatment of Solid Tumors: Preclinical and Clinical Investigations

References

• Kennedy K.A., Teicher B.A., Rockwell S., Sartorelli A.C. The hypoxic tumor cell: a target for selective cancer chemotherapy. Biochemical Pharmacol. 1980; 29: 1
   PubMed Web of Science ®Google Scholar
• Dillman R.O., Shawler D.L., Johnson D.E., Meyer D.L., Koziol J.A., Frincke J.M. Preclinical trials with combinations and conjugates of T101 monoclonal antibody and doxorubicin. Cancer Res. 1986; 46: 4886
   PubMed Web of Science ®Google Scholar
• Liposomes as Drug Carriers: Recent Trends and Progress, G. Gregoriadis. J. Wiley and Sons, Chichester 1988
   Google Scholar
• Ranade V.V. Drug delivery systems1. Site-specific drug delivery using liposomes as carriers. J. Cancer Pharmacol. 1989; 29: 685
   Google Scholar
• Senior J.H. Fate and behavior of liposomes in vivo: a review of controlling factors. CRC Critical Reviews in Therapeutic Drug Carrier Systems 1987; 3: 123
   PubMed Web of Science ®Google Scholar
• Connor J., Huang L. pH-sensitive immunoliposomes as an efficient and target-specific carrier for antitumor drugs. Cancer Res. 1986; 46: 3431
   PubMed Web of Science ®Google Scholar
• Nayar R., Fidler I., Schroit A.J. Potential applications of pH-sensitive liposomes as drug delivery systems. “Liposomes as Drug Carriers: Recent Trends and Progress.”, G. Gregoriadis. J. Wiley and Sons, Chichester 1988; 771
   Google Scholar
• Torchilin V.P., Zhou F., Huang L. pH-sensitive liposomes. J. Liposome Res. 1993; 3: 201
   Google Scholar
• Ghose T., Singh M., Faulkner G., Goundalkar A., Mezei M. Antibody-aided liposomal drug delivery. “Liposomes as Drug Carriers: Recent Trends and Progress.”, G. Gregoriadis. J. Wiley and Sons, Chichester 1988; 697
   Google Scholar
• Papahadjopoulos D., Gabizon A. Targeting of liposomes to tumor cells, in vivo. Ann. N.Y. Acad. Sci. 1987; 507: 64
   PubMed Web of Science ®Google Scholar
• Allen T.M., Chonn A. Large unilamellar liposomes with low uptake into the reticuloendothelial system. Fed. Eur. Biochem. Soc. 1987; 223: 42
   PubMed Web of Science ®Google Scholar
• Heath T.D., Macher B.A., Papahadjopoulos D. Covalent attachment of immunoglobulins to liposomes via glycosphingolipids. Biochim. Biophys. Acta 1981; 640: 66
   PubMed Web of Science ®Google Scholar
• Weinstein J.N., Magin R.L., Yatvin M.B., Zaharko D.S. Liposomes and local hyperthermia: selective delivery of methotrexate to heated tumors. Science 1973; 204: 188
   Google Scholar
• Wu M.S., Robbins J.C., Bugianesi R. L., Ponpipom M.M., Shen T.Y. Modified in vivo behavior of liposomes containing synthetic glycolipids. Biochim. Biophys. Acta 1981; 674: 19
   PubMed Web of Science ®Google Scholar
• Mauk M.R., Gamble R.C. Preparation of lipid vesicles containing high levels of entrapped radioactive cations. Anal. Biochem. 1979; 94: 302
   PubMed Web of Science ®Google Scholar
• Proffitt R.T., Williams L.E., Presant C.A., Tin G.W., Uliana J.A., Gamble R.C., Baldeschwieler J.D. Liposomal blockage of the reticuloendothelial system: improved tumor imaging with small unilamellar vesicles. Science 1983; 220: 502
   PubMed Web of Science ®Google Scholar
• Proffitt R.T., Williams L.E., Presant C.A., Tin G.W., Uliana J.A., Gamble R.C., Baldeschwieler J.D. Tumor-imaging potential of liposomes loaded with In-111-NTA: biodistribution in mice. J. Nucl. Med. 1983; 24: 45
   PubMed Web of Science ®Google Scholar
• Mauk M.R., Gamble R.C. Stability of lipid vesicles in tissues of the mouse: a x-ray perturbed angular correlation study. Proc. Natl. Acad. Sci. U.S.A. 1979; 76: 765
   PubMed Web of Science ®Google Scholar
• Williams L.E., Proffitt R.T., Lovisatti L. Possible applications of phospholipid vesicles (liposomes) in diagnostic radiology. J. Nucl. Med. Allied Sci. 1984; 28: 35
   PubMedGoogle Scholar
• Kerr D.J., Kaye S.B. Aspects of cytotoxic drug penetration, with particular reference to anthracyclines. Cancer Chemother. Pharmacol. 1987; 19: 1
   PubMed Web of Science ®Google Scholar
• Papahadjopoulos D., Cowden M., Kimelberg H. Role of cholesterol in membranes, effects on phospholipid-protein interactions, membrane permeability and enzymatic activity. Biochim. Biophys. Acta 1973; 330: 8
   PubMedGoogle Scholar
• Papahadjopoulos D., Jacobson K., Nir S., Isac T. Phase transitions in phospholipid vesicles. Fluorescence polarization and permeability measurements concerning the effect of temperature and cholesterol. Biochim. Biophys. Acta 1973; 311: 330
   Google Scholar
• Turner A.F., Presant C.A., Proffitt R.T., Williams L.E., Winsor D.W., Werner J.L. In-111-Iabeled liposomes: dosimetry and tumor depiction. Radiology 1988; 166: 761
   PubMed Web of Science ®Google Scholar
• Williams L.E., Duda R.B., Proffitt R.T., Beatty B.G., Beatty J.D., Wong J.Y.C., Shively J.E., Paxton R.J. Tumor uptake as a function of tumor mass: a mathematic model. J. Nucl. Med. 1988; 29: 103
   PubMed Web of Science ®Google Scholar
• Presant C.A., Proffitt R.T., Turner A.F., Williams L.E., Winsor D., Werner J.L., Kennedy P., Wisemand C., Gala K., McKenna R.J., Smith J.D., Bouzaglou S.A., Callahan R.A., Baldeschwieler J.D., Crossley R.J. Successful imaging of human cancer with indium-111-labeled phospholipid vesicles. Cancer (Phila.) 1988; 62: 905
   PubMed Web of Science ®Google Scholar
• Presant C.A., Blayney D., Proffitt R.T., Turner A.F., Williams L.E., Nadel H.I., Kennedy P., Wiseman C., Gala K., Crossley R.J., Preiss S.J., Ksionski G.E., Presant S.L. Preliminary report: Kaposi sarcoma and lymphoma in AIDS with indium-111-labeled liposomes. Lancet 1990; 335: 1307
   PubMed Web of Science ®Google Scholar
• Kaplan L. Neoplastic complications of HIV disease. Infections in Medicine 1992; 9(Supl. F)20
   Google Scholar
• Warren B.A. The vascular morphology of tumors. “Tumor Blood Circulation: Angiogenesis, Vascular Morphology, and Blood Flow of Experimental and Human Tumors.”, H-I. Peterson. CRC Press Inc., Boca Raton 1979; 1
   Google Scholar
• Forssen E.A., Coulter D.M., Proffitt R.T. Selective in vivo localization of daunorubicin small unilamellar vesicles in solid tumors. Cancer Res. 1992; 52: 3255
   PubMed Web of Science ®Google Scholar
• Kaye S.B., Boden J.A., Ryman B.E. The effect of liposome (phospholipid vesicle) entrapment of actinomycin-D and methotrexate on the in vivo treatment of sensitive and resistant solid murine tumors. Eur. J Cancer 1981; 17: 279
   Google Scholar
• Ganapathi R., Krishan A., Wodinsky I., Zubrod C.G., Lesko L.J. Effect of cholesterol content on antitumor activity and toxicity of liposome-encapsulated 1-β-D-arabinofuranosylcytosine in vivo. Cancer Res. 1980; 40: 630
   PubMed Web of Science ®Google Scholar
• Rustum Y.M., Dave C., Mayhew E., Papahadjopoulos D. Role of liposome type and route of administration in the antitumor activity of liposome-entrapped 1-β-D-arabinofuranosylcytosine against mouse L1210 leukemia. Cancer Res. 1979; 39: 1390
   PubMed Web of Science ®Google Scholar
• Forssen E.A., Tökés Z.A. Use of anionic liposomes for reduction of chronic doxorubicin-induced cardiotoxicity. Proc. Nat. Acad. Sci. U.S.A. 1981; 78: 1873
   PubMed Web of Science ®Google Scholar
• Rahman A., Kessler A., More N., Sikic B., Rowden G., Woolley P., Schein P.S. Liposomal protection of adriamycin-induced cardiotoxicity in mice. Cancer Res. 1980; 40: 1532
   PubMed Web of Science ®Google Scholar
• Gabizon A., Meshorer A., Barenholz Y. Comparative long-term study of the toxicities of free and liposome-associated doxorubicin in mice after intravenous administration. J. Natl. Cancer Inst. 1986; 77: 459
   Google Scholar
• Storm G., Roerdink F.H., Steerenberg P.A., de Johng W.H., Crommelin D.J.A. Influence of lipid composition on the antitumor activity exerted by doxorubicin-containing liposomes in a rat solid tumor model. Cancer Res. 1987; 47: 3366
   PubMed Web of Science ®Google Scholar
• Forssen E.A., Tökés Z.A. In vitro and in vivo studies with adriamycin liposomes. Biochem. Biophys. Res. Commun. 1979; 91: 1295
   PubMed Web of Science ®Google Scholar
• Forssen E.A., Tökés Z.A. Improved therapeutic benefits of doxorubicin by entrapment in anionic liposomes. Cancer Res. 1983; 3: 546
   Google Scholar
• Storm G., van Bloois L., Steerenberg P.A., van Etten E., de Groot G., Crommelin D.J.A. Liposome encapsulation of doxorubicin: pharmaceutical and therapeutic aspects. J. Contrl. Release 1989; 9: 215
   Web of Science ®Google Scholar
• van Hoesel Q.G.C.M., Steerenberg P.A., Crommelin D.J.A., van Dijk A, van Oort W., Klein S., Douze J.M.C., de Wildt D.J., Hillen F.C. Reduced cardiotoxicity and nephrotoxicity with preservation of antitumor activity of doxorubicin entrapped in stable liposomes in the LIEU/M Wsl rat. Cancer Res. 1984; 44: 3698
   PubMed Web of Science ®Google Scholar
• Gabizon A., Goren D., Fuks Z., Barenholz Y., Dagan A., Meshorer A. Enhancement of adriamycin delivery to liver metastatic cells with increased tumoricidal effect using liposomes as drug carriers. Cancer Res. 1983; 43: 4730
   PubMed Web of Science ®Google Scholar
• Gabizon A., Dagan A., Goren D., Barenholz Y., Fuks Z. Liposomes as in vivo carriers of adriamycin: reduced cardiac uptake and preserved antitumor activity in mice. Cancer Res. 1982; 42: 4734
   PubMed Web of Science ®Google Scholar
• Kriby C., Clarke J., Gregoriadis G. Effect of the cholesterol content of small unilamellar liposomes on their stability in vivo and in vitro. Biochem. J. 1980; 186: 591
   PubMedGoogle Scholar
• Vaage J., Mayhew E., Lasic D., Martin F. Therapy of primary and metastatic mouse mammary carcinoma with doxorubicin encapsulated in long circulating liposomes. Int. J. Cancer 1992; 51: 942
   PubMed Web of Science ®Google Scholar
• Weiss R.B., Bruno S. Daunorubicin treatment of adult solid tumors. Cancer Treatment Reports 1981; 65(Supl. 4)25
   PubMedGoogle Scholar
• Von Hoff D.D., Rozenweig M., Slavik M., Muggia F.M. Activity of daunorubicin in solid tumors. J. Am. Med. Assoc. 1976; 236: 1693
   Google Scholar
• Bosanquet A.G. Stability of solutions of antineoplastic agents during preparation and storage for in vivo assays. Cancer Chemother. Pharmacol. 1986; 17: 1
   PubMedGoogle Scholar
• Forssen E.A. Chemotherapy with anthracycline-liposomes. “Liposomes as Drug Carriers: Recent Trends and Progress.”, G. Gregoriadis. J. Wiley and Sons, Chichester 1988; 355
   Google Scholar
• Casazza A.M. Experimental evaluation of anthracycline analogues. Cancer Treat. Rpts. 1979; 63: 835
   PubMedGoogle Scholar
• Corbett T.H., Griswold D.P., Jr., Roberts B.J., Peckham J.C., Schabel E.M., Jr. Biology and therapeutic response of a mouse mammary adenocarcinoma (16/C) and its potential as a model for surgical adjuvant chemotherapy. Cancer Treat. Rep. 1978; 62: 1471
   Google Scholar
• Rideout D.C., Calogeropoulou T. Synergism and Antagonism through direct bond formation between two agents in situ. “Synergism and Antagonism in Chemotherapy.”, T-C Chou, D.C. Rideout. Academic Press, San Diego 1991; 507
   Google Scholar
• Tsou K.C., Lo K.W., Ledis S.L., Miller E.E. Indigogenic phosphodiesters as potential chromogenic cancer chemotherapeutic agents. J. Med. Chem. 1972; 15: 1221
   PubMedGoogle Scholar
• Gibaldi M., Perrier D. Pharmacokinetics, Drugs and the Pharmaceutical Sciences Vol. 1. Marcel Dekker, Inc., New York 1975
   Google Scholar
• Tökés Z.A., St. Péteri A.K., Todd J.A. Availability of liposome content to the nervous system. Liposomes and the blood-brain barrier. Brain Res. 1980; 188: 282
   Google Scholar
• Ipsen J.H., Karlström G., Mouritsen O.G., Wennerström H., Zuckermann M.J. Phase equilibria in the phosphatidylcholine-cholesterol system. Biochim. Biophys. Acta 1987; 905: 162
   PubMed Web of Science ®Google Scholar
• Weiss L., Orr F. W., Honn K.V. Interactions between cancer cells and the microvasculature: a rate-regulator for metastasis. Clin. Exp. Metastasis 1989; 7: 127
   PubMed Web of Science ®Google Scholar
• Friedman-Kien A.E., Laubenstein L.J., Rubinstein P. Disseminated Kaposi's sarcoma in homosexual men. Ann. Inter. Med. 1982; 96: 693
   PubMed Web of Science ®Google Scholar
• Presant C.A., Scolaro M., Kennedy P., Blayney D.W., Flanagan B., Lisak J., Presant J. Liposomal daunorubicin treatment of HIV-associated Kaposi's sarcoma. Lancet 1993; 341: 1242
   PubMed Web of Science ®Google Scholar
• Balazsovits J.A.E., Mayer L.D., Bally M.B., Cullis P.R., McDonell M., Ginsberg R.S., Falk R.E. Analysis of the effect of liposome encapsulation on the vesicant properties, acute and cardiac toxicities, and antitumor efficacy of doxorubicin. Cancer Chemother. Pharmacol. 1989; 23: 81
   Google Scholar
• Forssen E.A., Tokes Z.A. Attenuation of dermal toxicity of doxorubicin by liposome encapsulation. Cancer Treat. Rpts. 1983; 67: 481
   PubMedGoogle Scholar
• Watson E.J., Chan K.K. Rapid analytic method for Adriamycin and metabolites in human plasma by a thin-film fluorescence scanner. Cancer Treat. Rep. 1976; 60: 1611
   PubMedGoogle Scholar
• Alberts D.S. The pharmacokinetics of daunorubicin in man. Clin. Pharmacol. Therap. 1971; 12: 96
   PubMedGoogle Scholar
• Skinner S.A., Tutton P.J.M., O'Brien P.E. Microvascular architecture of experimental colon tumor in the rat. Cancer Res. 1990; 50: 2411
   PubMed Web of Science ®Google Scholar
• Less J.R., Skalak T.C., Sevick E.M., Jain R.K. Microvascular architecture in a mammary carcinoma: branching patterns and vessel dimensions. Cancer Res. 1991; 51: 265
   PubMed Web of Science ®Google Scholar
• Poste G. Liposome targeting in vivo: problems and opportunities. Biol. Cell 1983; 47: 19
   Web of Science ®Google Scholar
• Poste G., Bucana C., Raz A., Bugelski P., Kirsh R., Fidler I.J. Analysis of the fate of systemically administered liposomes and implications for their use in drug delivery. Cancer Res. 1982; 42: 1412
   PubMed Web of Science ®Google Scholar
• Gill P., Naidu Y.M., Salahudin S.Z. Current Opinion is oncology: recent advances in AIDS-related Kaposi's sarcoma. Current Science 1990; 2: 116
   Google Scholar
• Hwang K.J., Padki M.M., Chow D.D., Essien H.E., Lai J.Y., Beaumier P.L. Uptake of small liposomes by non-reticuloendothelial tissues. Biochim. Biophys. Acta 1987; 901: 88
   PubMed Web of Science ®Google Scholar
• Krown S.E. The role of interferon in the therapy of epidemic Kaposi's sarcoma. Seminars in Oncology 1987; 14: 27
   PubMedGoogle Scholar
• Northfelt D. W., Kahn J.O., Volberding P.A. Treatment of AIDS-related Kaposi's sarcoma. Hematology/Oncology Clinics of North America 1991; 5: 297
   PubMedGoogle Scholar
• Hengge U.R., Brockmeyer N.H., Raßhofer R., Goos M. Fatal hepatic failure with liposomal doxorubicin. Lancet 1993; 341: 383
   PubMed Web of Science ®Google Scholar
• Sharma D., Muggia F., Lucci L., Chan K., Forssen E., Gill P. Liposomal daunorubicin: Tolerance and clinical effects in AIDS-related Kaposi's sarcoma during a phase I study. Proc. Am. Soc. Clin. Oncol. 1990; 9: 9, 1990
   Google Scholar